A.J. Rice
Stock Analyst at Credit Suisse
Total Price Targets
8
Stocks Covered
8
Sectors
Healthcare
Most Recent
Dec 13, 2021
Stocks Covered by A.J. Rice
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| CNC | Centene Corp. | $86.00 | $62.37 | +37.9% | 1 | Dec 13, 2021 |
| CVS | CVS Health Corp. | $120.00 | $104.92 | +14.4% | 1 | Dec 10, 2021 |
| CI | Cigna Corporation | $300.00 | $281.22 | +6.7% | 1 | Nov 8, 2021 |
| HUM | Humana Inc. | $513.00 | $364.86 | +40.6% | 1 | Nov 4, 2021 |
| ELV | Elevance Health Inc. | $486.00 | $376.86 | +29.0% | 1 | Oct 21, 2021 |
| UNH | UnitedHealth Group Incorporated | $495.00 | $416.57 | +18.8% | 1 | Oct 15, 2021 |
| DGX | Quest Diagnostics Incorporated | $150.00 | $234.44 | -36.0% | 1 | Sep 9, 2021 |
| UHS | Universal Health Services, Inc. | $181.00 | $168.57 | +7.4% | 1 | Jul 27, 2021 |
Recent Activity
- Dec 13, 2021— Set$86.00price target onCNC(Centene Corp.)
- Dec 10, 2021— Set$120.00price target onCVS(CVS Health Corp.)
- Nov 8, 2021— Set$300.00price target onCI(Cigna Corporation)
- Nov 4, 2021— Set$513.00price target onHUM(Humana Inc.)
- Oct 21, 2021— Set$486.00price target onELV(Elevance Health Inc.)
- Oct 15, 2021— Set$495.00price target onUNH(UnitedHealth Group Incorporated)
- Sep 9, 2021— Set$150.00price target onDGX(Quest Diagnostics Incorporated)
- Jul 27, 2021— Set$181.00price target onUHS(Universal Health Services, Inc.)
Frequently Asked Questions
Who is A.J. Rice?
A.J. Rice is a stock analyst at Credit Suisse covering 8 stocks primarily in Healthcare. They have issued 8 price targets since Jul 27, 2021.
What stocks does A.J. Rice cover?
A.J. Rice currently covers 8 stocks, including CNC, CVS, CI, HUM, ELV.
What is A.J. Rice's latest price target?
A.J. Rice's most recent price target was $86.00 on CNC (Centene Corp.), set on Dec 13, 2021.
What is A.J. Rice's highest price target?
A.J. Rice's highest issued price target is $513.00 on HUM, set on Nov 4, 2021.
More Analysts at Credit Suisse
Coverage based on publicly published price targets. Not investment advice.